Bioxcel Therapeutics, INC Form 4 insider transactions

Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, was granted stock options to purchase 1,875 shares of common stock on July 22, 2024.

Director David J. Mack reports a transaction involving BioXcel Therapeutics, Inc. stock, specifically the vesting and disposal of Restricted Stock Units (RSUs).

Richard Steinhart, CFO of BioXcel Therapeutics, reports the vesting and acquisition of common stock through restricted stock units.

Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc., reports the vesting and acquisition of common stock through restricted stock units.

Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the vesting of restricted stock units.

BioXcel Therapeutics CEO Vimal Mehta reports the vesting and conversion of restricted stock units into common stock.

Director David J. Mack reports the vesting of restricted stock units and subsequent disposal of shares.

Director David J. Mack reports the vesting of restricted stock units in BioXcel Therapeutics, resulting in the acquisition of 27,089 shares of common stock.

Rajiv Patni, a director at BioXcel Therapeutics, was granted options to purchase 44,000 shares of common stock on January 15, 2025.

BioXcel Therapeutics CEO, Vimal Mehta, was granted options to purchase 660,000 shares of common stock on January 7, 2025.

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, was granted options to purchase 270,000 shares of common stock.

BioXcel Therapeutics' Chief Financial Officer, Richard Steinhart, was granted options to purchase 270,000 shares of common stock.

BioXcel Therapeutics director David Mack acquired 27,089 shares of common stock through the vesting of restricted stock units.

BioXcel Therapeutics executive Vincent O'Neill exercised stock options and sold a portion of the acquired shares, according to a recent SEC filing.

BioXcel Therapeutics CEO Vimal Mehta executed multiple stock transactions, including acquisitions and sales, under a pre-arranged 10b5-1 trading plan.

BioXcel Therapeutics' Chief Financial Officer, Richard Steinhart, executed multiple stock transactions, including the vesting of restricted stock units and sales of common stock, under a pre-arranged 10b5-1 trading plan.

BioXcel Therapeutics' Chief Legal Officer, Javier Rodriguez, sold a portion of his holdings in company stock under a pre-arranged 10b5-1 trading plan.

BioXcel Therapeutics' Chief Scientific Officer, Frank Yocca, executed multiple stock transactions, including the vesting of restricted stock units and sales of common stock, under a pre-arranged 10b5-1 trading plan.

Director David J. Mack of BioXcel Therapeutics, Inc. reported the acquisition of 27,089 shares of common stock through the vesting of restricted stock units.

Director David Mack of BioXcel Therapeutics reported the acquisition of restricted stock units and the vesting of common stock.

David J. Mack, a director at BioXcel Therapeutics, was granted 325,077 restricted stock units (RSUs) on November 21, 2024, which will vest monthly over the next year.

Matthew Wiley, Chief Commercial Officer of BioXcel Therapeutics, reports acquisition of shares through vested restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Javier Rodriguez, Chief Legal Officer of BioXcel Therapeutics, sold shares of common stock following the vesting of restricted stock units.

Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports acquisition of shares through vested restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Richard Steinhart, CFO of BioXcel Therapeutics, reports acquisition of shares through vested restricted stock units and subsequent sale of shares under a pre-arranged trading plan.

Vincent O'Neill, an executive at BioXcel Therapeutics, sold 5,556 shares of common stock after the vesting of 21,250 restricted stock units.

Frank Yocca, Chief Scientific Officer of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

BioXcel Therapeutics CEO Vimal Mehta reports the acquisition and disposal of common stock and restricted stock units, including sales under a pre-arranged 10b5-1 trading plan.

Richard Steinhart, CFO of BioXcel Therapeutics, reports the acquisition and disposal of common stock and restricted stock units.

Javier Rodriguez, Chief Legal Officer, Senior Vice President, and Corporate Secretary of BioXcel Therapeutics, Inc., reports the sale of common stock and vesting of restricted stock units.